Sustained Local Delivery of Structurally Diverse HIV-1 Microbicides Released from Sublimation Enthalpy Controlled Matrices by Simi Gunaseelan et al.
RESEARCH PAPER
Sustained Local Delivery of Structurally Diverse HIV-1 Microbicides
Released from Sublimation Enthalpy Controlled Matrices
Simi Gunaseelan & Philippe A. Gallay & Michael D. Bobardt & Charlene S. Dezzutti & Timothy Esch & Richard Maskiewicz
Received: 27 February 2012 /Accepted: 21 May 2012
# The Author(s) 2012. This article is published with open access at Springerlink.com.
ABSTRACT
Purpose Use of coital-dependent products to prevent HIV-1
transmission has resulted in mixed success. We hypothesize
that incorporation of antiviral drug candidates into a novel
controlled delivery system will prolong their activity, making
their use coital independent, thus increasing their chance of
prophylactic success.
Methods Tenofovir, emtricitabine, and C5A peptide HIV
microbicides were mechanically incorporated into matrices
comprising a series of subliming solids. Matrix sublimation rates
and drug release rates were measured in three in vitro and one
in vivo environments intended to model human vaginal interior.
Antiviral activity studies evaluating matrix incorporated micro-
bicides were performed using in vitro cell cultures and human
ectocervical explants.
Results Drug release rates were identical to matrix sublimation
rates, and were zero order. Differences in matrix material
sublimation enthalpies determined drug release and matrix
erosion rates in a thermodynamically definable manner, in vitro
and in vivo. Durations of release ranging from several days to
several months were readily achieved. Prolonged duration of
anti HIV-1 activity was shown for matrix incorporated micro-
bicides, using ectocervical explant and cell culture models of
HIV-1 infection.
Conclusion Subliming solid matrices show promise as a deliv-
ery system providing multi month intravaginal release of a wide
range of HIV-1 microbicides.
KEY WORDS enthalpically controlled release . HIV-1 .
intravaginal delivery . prolonged antiviral effect . subliming solid
matrix
INTRODUCTION
Prevention of AIDS infection in healthy women during
intercourse with HIV positive partners through use of con-
doms or topical applications of antiviral microbicide contin-
ues to meet with limited success for a number of personal
and social reasons (1). The majority of HIV-1 microbicides
delivery systems under current clinical evaluation employ
coital-dependent quick release formulations administered in
the form of aqueous-based gels applied shortly prior to and/
or after coitus. Such delivery systems usually fail to provide
inhibitory concentrations for a sufficient period of time to
avert transmission that may be a result of repeated sexual
activity, and the viral shedding typical of acute HIV-1
infection, and therefore require frequent and repeated
microbicide application (2). Windows of opportunity for
untreated viral spread and progression of infection can also
occur, ultimately requiring a switch from prophylaxis to
more problematic systemic therapy, using several of the
same antiviral agents employed as HIV-1 microbicides.
These limitations can be resolved by employing coitally
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independent sustained and extended duration delivery sys-
tems intended to simplify and assure infection prevention.
Several potential products could ultimately utilize an intra-
vaginal ring, which would be inserted into the vaginal cavity
well before coitus and assist in the local retention of the
administered dose. Sustained release of and prolonged pro-
tection by several possible microbicides would occur
through the intra-ring incorporation of the drug delivery
system described herein. Such sustained local delivery of
microbicides should ultimately be able to ensure that inhib-
itory anti-HIV-1 agent concentrations are constantly avail-
able in situ to continuously block the early steps of sexual
HIV-1 infection (2).
Effective prophylaxis against sexually transmitted HIV-1
entails improved subject compliance through continuous
and prolonged duration delivery of periodically adminis-
tered HIV-1 microbicide (3,4). Continuous intravaginal re-
lease in a coitally independent manner can improve efficacy
but is constrained by the drug delivery technologies which
are available. The goal of this study was to identify, and
perform proof-of-concept characterization of a drug deliv-
ery technology demonstrating controlled release of multiple
microbicides while possessing fewer limitations than any of
the currently employed delivery methods. Current problem
areas with existing techniques for sustained drug release
include rates of intravaginal microbicide delivery which
typically decrease substantially in the course of their pro-
longed release (5), and rates and durations of microbicide
sustained release based on hindered diffusion often being
more dependent on the size, structure, and physiochemical
properties of a candidate antiviral drug than on the intrinsic
performance of the delivery system. This often makes
achievement of specific therapeutic release rates and dura-
tions problematic, especially for high molecular weight or
hydrophilic agents released from polymer monoliths (6,7).
Other problems confounding attempts at providing repro-
ducible and constant intravaginal drug release rates or
durations include variability of intravaginal physiological
state such as local pH (range of 3.0 to 5.5), hydration state,
and flora (8–10), all of which would affect durations of
release/efficacy through variability in the erosion rate of a
drug-incorporating matrix/capsule where release of drug is
achieved through delivery system dissolution/hydrolysis.
Recent identification and early clinical evaluation of peptide
and protein based HIV-1 microbicides further complicates
efforts towards development of sustained release versions of
novel and potentially highly selective HIV-1 prophylactic
agents (11) due to their generally poor chemical and physical
stability in the intravaginal milieu upon bolus administration
of simple formulations and during long-duration delivery (12).
A new process for sustained release of drugs into a
defined environment, employing neither conventional drug
diffusion nor matrix/membrane dissolution (13), has been
identified and holds promise towards solving these prob-
lems. This process entails incorporation of drug into a
matrix, and subsequent matrix erosion, but differs in that
drug release is not due to either hydrolysis or dissolution of
the matrix material, or due to diffusion of water into or drug
out of a non-erodable matrix. Rather, release of drug from
chemically inert and water insoluble matrices occur by
surface erosion achieved through sublimation (direct con-
version of solid to a gas) of matrix, allowing sequentially
exposed drug particles to be delivered to the local environ-
ment of the administration site. The hypothesis is that a
novel delivery system based on drug-loaded matrix sublima-
tion can provide release rates independent of drug molecule
size and physicochemical properties, but instead be primar-
ily dependent on enthalpies of sublimation of specific matrix
materials. A secondary hypothesis is that measures of long
duration release obtained using unconventional in vitro mod-
els can translate into HIV microbicide activity prolongation
ex vivo, and are reflective of sublimation (and mass transport)
processes which occur intravaginally.
Subliming solid matrices consist of hydrophobic, chem-
ically and biologically un-reactive organic substances (14),
which due to their having weak intermolecular interactions
in the solid state, can directly transform into vapor at phys-
iological temperature. Examplary molecules possessing this
attribute comprise several perfluorocarbons and cyclic/
branched alkanes achieving substantially spherical structural
conformations. Subliming matrices chosen for demonstrat-
ing the feasible range of microbicide controlled release
durations include norbornane (NOR), hexamethylethane
(HME), hexamethylcyclotrisiloxane (HMCS), perfluoroun-
decane (PF-11), perfluorododecane (PF-12), and cyclodode-
cane (CDD); between them possessing a sublimation
enthalpy range between 40 and 76 kJ/mol (15–17).
Anti-HIV drug candidates, emtricitabine and tenofovir,
which have achieved clinical confirmation of microbicidal
efficacy via topical (18) and oral administration (19), were
chosen to evaluate delivery kinetics from subliming matrices,
along with the novel but chemically unstable peptide micro-
bicide C5A (20). These drugs were also employed to dem-
onstrate that sublimation based sustained release in cell and
tissue cultures can extend anti-HIV-1 activity relative to the
marginally prophylactic durations achieved by single bolus
administration of simple aqueous formulations at a given
dose. Choice of HIV-1 microbicides for evaluation of this
novel drug delivery system was additionally based on their
possessing significant differences in physicochemical proper-
ties, allowing the abovementioned demonstration that sub-
liming solid matrix based control of release rate is
independent of the nature of the drug substance. We eval-
uated release of tenofovir disoproxil fumarate (TDF) a
charged but poorly soluble molecule [M.W.0287], emtrici-
tabine (FTC) an uncharged but highly water soluble
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molecule [M.W.0247], in addition to the biotinylated ver-
sion of a novel microbicide C5A (bC5A) a hydrophobic, low
solubility, chemically reactive eighteen amino acid peptide
[M.W.02,537].
Demonstration of a broad range of controlled release
rates and associated prolongations of antiviral efficacy for
the above microbicide molecules incorporated within a se-
ries of subliming matrices, should provide sufficient ratio-
nale for critical follow-up studies examining the long-term
intravaginal and systemic safety of the chosen subliming
solid substances and their use for prolonged drug delivery.
The results discussed herein will also serve as the foundation
for our ultimate goal, development of robust sexual HIV
prophylaxis using an intravaginal-ring-based sustained re-
tention system, incorporating subliming matrices which will




CDD was obtained from Kremer Gmbh (Aichstettin, Ger-
many). PF-11 and PF-12 were obtained from Exfluor Re-
search Corporation (Round Rock, Texas, USA). ADM,
NOR, HME, and HMCS were purchased from Sigma-
Aldrich (St. Louis, Missouri, USA). Matrix materials were
further purified by resublimation at atmospheric pressure.
FTC and bC5A [SWLRDIWDWICEVLSDFK-Biotin]
were obtained from the laboratory of Dr. Philippe Gallay
(The Scripps Research Institute, California, USA). TDF was
provided by CONRAD (Arlington, Virginia, USA). HPLC
grade acetonitrile was purchased from Fisher Scientific (Pitts-
burgh, Pennsylvania, USA). Trifluoroacetic acid and formic
acid were obtained from EMD Chemicals (Gibbstown, New
Jersey, USA), and Sigma-Aldrich (St. Louis, Missouri, USA)
respectively. Nano pure water (0.2 micron) was obtained from
Barnstead NANOpure Water Purification Systems (Asheville,
North Carolina, USA).
Preparation of Cylindrical Matrix Formulations
Incorporating Different Drugs for Release Rate
Determinations
The three drugs were micronized using mortar and pestle.
Each of the powders were then homogenously dispersed into
a given subliming matrix powder at 1.0 wt/wt percent
loading through serial dilution in a mortar and pestle. 5×
5 mm cylinders of drug-loaded matrices which were longi-
tudinally enclosed in impermeable PVC sheaths (providing
constant sublimation surface areas of 0.39 cm2 per cylinder)
were prepared by weighing drug loaded powders (to yield
final pellet weights of 400 mg for PF-11 and PF-12 matrices,
and 175 mg for NOR, HMCS, and CDD matrices) into a
steel mold, and then compressing with a force of 545 lbs
transmitted by the corresponding cylindrical die for 1 s,
using a Carver Hydraulic Press (Carver Inc., Wabash,
Indiana, USA).
Preparation of Placebo and Drug-Loaded Discs for Ex
Vivo and In Vivo Evaluations
Test samples for ex vivo studies having dimensions of 5×5×
3 mm, and containing 0.1% microbicide, were prepared as
previously described, to yield final pellet weight of 400 mg
for PF-11 and PF-12 matrices, and 175 mg for ADM,
HMCS and CDD matrices. Placebo (non drug loaded)
cylinders for intravaginal sublimation rate determinations
were prepared in a manner identical to the one employed
for cylinders and discs used for in vitro and ex vivo studies.
Cylinder dimensions were 7.5×15 mm and yielded target
pellet weights of 750 mg for NOR and HMCS based test
articles.
Matrix Sublimation and Drug Release Rate
Determination
In vitro determinations of matrix sublimation and drug re-
lease rates were performed in a model environment
intended to approximate limited hydration within the hu-
man vagina, where internal fluid volume is low (21) and
surface area is relatively high (22). Sublimation mediated
erosion of constant surface area matrix cylinders was there-
fore initiated and maintained through removal of sublimed
vapor from matrix surface by defined and reproducible
convection produced by air at 37°C and 100% relative
humidity. This convective environment is similar in terms
of mass transport to the one maintained during ex vivo
activity prolongation studies using human ectocervical
explants (see below). These two sublimation based models
are defined as “accelerated” relative to the convective
(sublimed vapor transport) environment present in vivo in
ewes, and in the relatively low gaseous mass transport
(partially sealed container) cell culture based efficacy studies
(again see below).
Uncapped glass scintillation vials containing PVC
encased subliming cylinders were withdrawn from the incu-
bator at periodic intervals, and reinserted after cylinder
gravimetry, and released drug recovery. Drug which was
exposed/released after each incubation interval was recov-
ered by rinsing each cylinder and surrounding vial surface
for 30 s with 4.0 ml of a (i) 50% acetonitrile/water solution,
for bC5A; and (ii) 10% acetonitrile/water solution, for FTC
and TDF. All gravimetric and release data are reported as
mean ± SEM (N04). Control experiments have shown that
Sustained Drug Delivery from Sublimable Matrices
released amounts of each of the employed drug substances
were completely dissolved by this procedure, without any
measurable concomitant dissolution of unsublimed matrix
cylinders.
Quantitation of Released Drugs
Amounts of released bC5A, FTC, and TDF (in rinse solutions)
were measured using a Waters Alliance HPLC system
(CLARITY software) equipped with a UV detector and a
reversed phase C18 column (Waters, Inertsil® ODS-2, 5 μm,
4.6×150 mm), quantitation being performed at 280 nm. Gra-
dient elution of peptide microbicide employed water contain-
ing 0.1% trifluoroacetic acid (solvent A), and acetonitrile
containing 0.1% formic acid (solvent B). A linear gradient
(t00 min, 5 B, 95% A; t02 min, 5% B, 95% A; t015 min,
95% B, 5% A; t016 min, 5% B, 95% A; t020 min stop)
employing a flow rate of 1.2 ml/min at 40°C was used. HPLC
quantitation of FTC and TDF were performed at ambient
temperature using an isocratic reversed phase method. 10%
acetonitrile in water containing 0.1% trifluoroacetic acid and
0.1% formic acid was used as mobile phase at a flow rate of
1.0 ml/min.
Intravaginal Matrix Sublimation in Sheep
Adult ewes (Non Pregnant Western Sheep, Nebeker
Ranch, Lancaster, California, USA) were employed, per
a IACUC approved protocol. Cylindrical pellets were
individually inserted into the vaginas of four 100–
150 lb adult ewes. Prior to insertion (one per ewe) each
matrix cylinder was placed in a fine fiber coarse weave
plastic netting pouch tied with suture, to facilitate recov-
ery. Cylinders were inserted using a commercial vaginal
pessary applicator, and recovered by hand. In vivo rates
of sublimation were determined by measuring cylinder
weight changes (after removal of netting) at periodic
intervals. Gravimetric data are reported as mean ± SEM
(N04).
Viability of Human Ectocervical Tissue
Human ectocervical tissue was acquired through an IRB-
approved protocol from surgical remainders. Polarized
explants were prepared as described (23,24). One 5×5×
3 mm disc was placed on the apical surface of the treated
explants with 100 μl of medium on the day of set-up and
cultured for 5 days. Matched controls, no treatment or
exposure to nonoxynol-9 (N9), were set-up in parallel. After
5 days, the solids were removed and the explants were
rinsed with HBSS. Viability was determined using the
MTT [1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan]
assay.
Viability of Cultured Human PBMC, Macrophages
and T-Lymphocytes
Cells were plated in clear-bottom 6-well plates (BD
Biosciences) in the presence or absence of matrix discs for
a week. Cell Quanti-MTT™ reagent (Gentaur) was added
and cells incubated for 4 h at 37°C. Solubilization solution
was added and plate shaken for 1 h at room temperature.
A570 nm was measured on a SpectraMax 384 Plus reader
(Molecular Devices). As control, cells were treated with
0.01% saponin for a week. No washes were performed to
maintain a continuous exposure of cells to solids.
Durations of Anti-HIV Activity in Human Ectocervical
Explants
Polarized explants were set-up in duplicate and one 5×5×
3 mm PF-11 disc was placed on the apical surface of the
explants with 100 μl of medium on the day of set-up and
cultured for 3 days, under conditions where both the tissue
surface and the applied subliming matrix were in direct
contact with air, which was in turn readily exchangeable
with the external atmosphere. In this sense, experimental
conditions for mass transport of sublimed vapor during
explants studies were similar to those present during “accel-
erated” in vitro sublimation and drug release rate determi-
nations. To model antiviral efficacy achievable by single
bolus administration of the drug, 5 μM of TFV or FTC
was added to the apical surface 1 h prior to the first HIV-1
exposure. Controls included untreated polarized explants,
and explants in continuous contact with placebo PF-11
discs. HIV-1BaL (5×10
4 TCID50) was applied apically and
all explants were cultured overnight. After culture, the
explants were washed and fresh medium added to the baso-
lateral compartment. Viral challenge was repeated three
additional times (4 total HIV-1 exposures) every 3 to 4 days
over 10 days. Discs remained on the apical surface until they
sublimed away (typically 11 days), but were still present at
cessation of challenge. Every 3 to 4 days, basolateral superna-
tant was collected and replenished through 21 days. The
basolateral supernatant was tested for HIV-1 replication by
p24gag ELISA (Perkin-Elmer, Inc. Waltham, MA). Results
are expressed as pg/ml of HIV-1 p24 release over 21 days.
The median ±95% confidence interval is shown. Explants
were fixed in formalin at 21 day and endpoint immunohisto-
chemistry for HIV-1 p24gag expressing cells was performed
(23,24). Pink deposits indicate HIV-positive cells.
Durations of Anti-HIV Activity in Human Macrophage
and TZM Reporter Cell Cultures
Macrophages were isolated from blood donors as described
previously (20) and placed in cell culture for a week for
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cellular differentiation into 6-well plates. Due to the need to
maintain sterility, only limited mass transport (air flow be-
tween wells and external atmosphere) of sublimed vapor was
possible, making this particular in vitro methodology more
comparable to the relatively slow convective processes
thought to occur intravaginally. Matrix discs or unformulat-
ed microbicides in aqueous solution were then added to
wells. At various time points (week 1 to 4), macrophages
were exposed to HIV-1 R5 GFP and infection analyzed
after 48 h by FACS (% of GFP-positive macrophages).
TZM reporter cells were placed into 6-well plates in cell
culture together with discs or unformulated drugs. At vari-
ous time points, supernatant aliquots were collected and
stored at −20°C. After 32 days, collected aliquots were
thawed and individually added to TZM reporter target cells
together with HIV-1 (JR-CSF 200 pg of p24). Cells
were washed after 3 h. Two days post-infection, TZM
cells were lysed and betagalactosidase activity in cell
lysate was quantified. Data (triplicate) are expressed in
relative light units. Results are representative of three inde-
pendent experiments.
RESULTS AND DISCUSSION
Sublimation of a water insoluble matrix surrounding,
entrapping, and eventually exposing drug particles as a
mechanism for sustained release has not previously been
considered. This is perhaps due to the perceived small range
of sublimation (and associated drug release) rates possible,
or due to perceived toxicity of solid compounds commonly
associated with sublimation (naphthalene, camphor). How-
ever, by employing matrix materials comprising volatile
spherical or globular and primarily alkane based molecules,
a large range of sublimation/drug release rates (days to
months) are envisioned, while putatively also providing and
maintaining complete biological and chemical protection of
matrix contents. Herein we determined sublimation and con-
comitant drug release rates for several volatile matrix materi-
als possessing enthalpies of sublimation ranging between
40 kJ/mol and 76 kJ/mol (17).
Our strategy towards collectively assessing this delivery
system’s potential for sustained intravaginal drug release
from subliming solid matrices, employed four models, and
entailed a range of local environment (administration site)
dependent convective transport rates. Relatively rapid mass
transport (via convection/diffusion of sublimed vapor away
from an eroding matrix surface) is required for sublimation
to be continuous, and is expected to be fast relative to the
intrinsic sublimation rates of studied matrix materials, in all
of the models employed in this study. 1) The first model
entailed “accelerated” (rapid convection) in vitro sublimation
and drug release into moist air. This controlled mass
transport procedure is designed to account for low fluid
volumes present within the vagina and concomitant low
intravaginal hydration state. Estimates of intravaginal hy-
dration (at steady state) range from 0.012 to 0.04 ml of
mucus per cm2 of intravaginal surface (21,22). This partic-
ular procedure was employed for all precise rate determi-
nations. 2) The second model also employed rapid
convection, and entailed ex vivo release of microbicides di-
rectly onto ectocervical tissue, to demonstrate prolonged
anti-HIV-1 activity and absence of matrix material toxicity.
3) The third model employed slow convection in vitro release
directly into cell culture medium to demonstrate prolonged
(>30 days) antiviral protection (and lack of toxicity) in sev-
eral cell types commonly employed for microbicide screen-
ing. 4) The final model entailed intravaginal incubations in
ewes, again entailing slow convection/diffusion conditions,
providing in vivo matrix sublimation rates, in a defined and
potentially relevant to women environment.
It should be noted that classical in vitro release meth-
odologies modeling systemic delivery entail immersion of
formulation/device samples into an aqueous or mixed
solvent “reservoir”, or “release medium”, thereby allow-
ing either matrix erosion or intramatrix diffusion, with
drug dissolution occurring during or immediately subse-
quent to release (13). Since exposure of matrix incorpo-
rated drug particles through intravaginal sublimation of
matrix surface does not require the mediation of liquid
water, the primary in vitro release technique employed for
this study is analogous to those often employed for in vitro
evaluation of transdermal drug delivery systems using
skin samples, where no aqueous solution component is present
during release rate measurements of patch incorporated
drugs (25).
Intravaginal dissolution of drugs exposed on matrix sur-
face subsequent to local sublimation should occur at rates
and to extents dependent on (assuming reasonable aqueous
drug solubility) degree of vaginal hydration and local fluid
volumes. A currently unanswered question is whether the
relatively high “accelerated” air convection (and sublimed
vapor transport) conditions present during both in vitro sub-
limation and release rate determinations, and ex vivo efficacy
prolongation measurements, adequately model the intrava-
ginal environment. The same question holds for the physi-
ological validity of relatively low convection environments
utilized during cell culture based efficacy prolongation
experiments, and occurring intravaginally during testing in
ewes, where excessive levels of viscous mucus were found to
be continuously present. Therefore, all performance measures
of subliming solid based drug delivery were, regardless of
model employed, conducted in a relative manner, separately
comparing structurally diverse drugs and then multiple sublim-
ing matrices to each other, thereby allowing the generalized
conclusions discussed below.
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Drug Substance Release Rates from Subliming
Matrices Were Independent of Active Agent
Molecular Size and Structure
Zero-order in vitro drug release from constant surface area
matrix cylinders, measured by amounts of embedded micro-
bicide particles progressively exposed on matrix pellet sur-
faces, appears to occur primarily through sublimation
mediated surface erosion, with release rates of structurally
dissimilar microbicide molecules being equal to the subli-
mation rate of the matrix into which they were incorporated,
and independent of the drugs physicochemical properties
(Fig. 1). Release rates of bC5A peptide, FTC and TDF were
very similar to each other, in spite of their structural diversity
and wide molecular size range, and equal to the sublimation
rates of the HMCS or PF-11 matrices within which they were
incorporated. This suggests that a particular duration of re-
lease was determined by the specific thermodynamic phase
change properties of HMCS and PF-11 matrices providing
sustained release.
Subliming matrix-based drug delivery compares favorably
against existing diffusion/hydrolysis/dissolution based drug de-
livery technologies. Drugs of high molecular weight or hydro-
philicity which typically diffuse through and release from water
insoluble matrices very slowly (5), can instead be delivered from
a given subliming solid at a rate independent of each potential
agent’s structure and properties. Examination of Fig. 1 in
particular demonstrates that i) release of a multi-charged but
low aqueous solubility eighteen amino acid peptide (C5A) from
a given matrix material occurs at a zero-order rate identical to
those measured for much smaller TDF and much more water
soluble FTC molecules, ii) that the release rates are identical to
the intrinsic matrix monolith sublimation rate, and iii) that the
equivalence of microbicide release and matrix sublimation
rates holds true for several structurally and enthalpically differ-
ent subliming solids.
Several existing processes for controlled delivery of drugs
can also achieve zero-order release rates independent of active
substance physicochemical attributes, entailing release of incor-
porated drug molecules/particles through the surface hydroly-
sis and/or dissolution of an entrapping matrix. Such release
mechanisms are however often affected and sometimes con-
trolled by local environment pH and hydration state (8–10).
Neither of these variables should be a factor in the sublimation
rates of the described hydrophobic matrix materials.
Use of subliming solids for drug delivery can also provide a
broad available range of microbicide release rates and dura-
tions. Figure 2a and b demonstrates that under employed in
vitro conditions, appropriate choice of matrix material can
achieve constant rates of both matrix sublimation and con-
comitant tenofovir release over durations as short as hours
(Fig. 2a) to as long as several months (Fig. 2b). Comparison of
data represented by filled and open symbols in both Fig. 2a
and b also conclusively demonstrates that the rate of micro-
bicide exposure/release is identical to the rate at which a given
matrix sublimes. This study has shown through the above in
vitro demonstration of zero-order release for three dissimilar
drug substances, incorporated into five different subliming
matrices, that volatile water-insoluble organic solids hold
promise as a multi month constant release rate delivery system
for potentially any number of intravaginally administered
HIV-1 microbicides.
The unprecedented range of release rates can be correlated
to enthalpies of sublimation specific to each employed matrix
material (Fig. 3), and allows a sublimation/release rate range of
more than 6 (base e) log units. This correlation also suggests
that the microbicide release mechanism is different from cur-
rently employed diffusion, dissolution, or hydrolytically medi-
ated erosion processes for drug delivery. Sustained release of
powdered drug substances through their incorporation into
hydrophobic matrix monoliths where liberation of active agent
occurs through sublimation driven surface erosion of matrix
material, has therefore not previously been employed for drug
delivery (26,27). Since the range of available sublimation rates
is broad, the potential for short-term but continuous and con-
trolled rectal delivery of HIV-1 microbicides also exists.
Fig. 1 Comparison of in vitro
(controlled convection) release
rates of bC5A, emtricitabine and
tenofovir, when incorporated
within HMCS (open symbols) or
PF-11 matrices (filled symbols).
Each plotted point represents a
mean ± SEM (N04).
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Matrix Sublimation and Incorporated Drug Substance
Release Rates Were Thermodynamically Controlled
by Matrix Sublimation Enthalpy
The key intrinsic variable affecting the rate of matrix subli-
mation and concomitant drug release appears to be the
sublimation enthalpy of the particular solid employed for
sustained microbicide delivery. As sublimation enthalpies
increased from 40 kJ/mol for NOR to 76 kJ/mol for
CDD, a broad range of sublimation rates and equivalent
release rates of incorporated TDF were achieved (Fig. 2a
and b). The natural log of each erosion/release rate
constant (mg/cm2/hr) was found to be a linear function of
matrix sublimation enthalpy (Fig. 3) indicating thermody-
namic control of the overall process, and explainable in
several ways.
The physical process of sublimation can be described and
quantitated employing transition state theory (28) where the
molecular rate of sublimation is described by Eqs. (1) and (2),
and where enthalpy of sublimation at body temperature is
larger than entropy of sublimation.
k ¼ kBT=hð Þexp ΔHsub=RTð Þexp ΔSsub=Rð Þ ð1Þ
ln k=T ¼ ΔHsub=RTþΔSsub=Rþ ln kB=h ð2Þ
The process of matrix erosion can also be described by
the Clausius-Clapyron equation (Eqs. 3 and 4), where the
vapor pressure of gaseous sublimed material at a matrix
Fig. 2 Comparison of tenofovir
release rates in vitro, to matrix
sublimation rates, for microbicide
incorporated within a series of (a)
rapidly subliming solids and (b)
slowly subliming solids.
Each plotted point represents
a mean ± SEM (N04).
Fig. 3 Natural log of matrix surface erosion rate constant (37°C, controlled
convection) as a function of matrix material sublimation enthalpy. Each plotted
point represents a mean value (N04).
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surface is a function of temperature, total pressure at the
subliming surface, and the sublimation enthalpy of the par-
ticular matrix material (29).
dP=dT ¼ PΔHsub=RT2 ð3Þ
ln P ¼ ΔHsub=RTþ c ð4Þ
Rate of matrix erosion (at a given temperature and pres-
sure) is directly proportional to the achieved vapor pressure of
sublimed molecules, and has been shown to be rate limiting
(controlling) when either in vitro or in vivo removal of sublimed
vapor by diffusive and convective processes is rapid relative to
the rate at which individual molecules of the matrix escape the
eroding surface (30). Similarly, the potential effect of varia-
tions in local temperature and pressure on matrix sublimation
becomes a non-issue when drug release occurs within the
body, where both mammalian temperature and internal pres-
sure are maintained at constant values through homeostasis
(31–33).
Net rates of sublimation based erosion in vivo can however
be influenced by diffusion and convection processes which,
post sublimation, remove gaseous or solvated matrix mole-
cules from the site of administration, perhaps leading to fractal
(but still linear) release kinetics (34,35). The potential retarding
influence of mass transport at a given administration site (see
below study in ewes) can however be compensated for by
appropriate choice of matrix material, and/or use of specific
sublimation rate enhancers.
Intravaginal Matrix Sublimations Occurred
at Constant and Thermodynamically Defined Rates
Accelerated in vitro microbicide release rate measurements
entail sublimation of matrix surface directly into 37°C,
100% relative humidity air slowly convecting under defined
and controlled conditions, and in direct communication with
the atmosphere. An intravaginal environment on the other
hand, while providing defined and homeostatically controlled
temperature and internal pressure at the matrix surface, pu-
tatively entails additional mass transport of sublimed matrix
vapors away from the eroding surface via a series of diffusion
and convection steps typically observed for implanted devices
(36,37). Adult ewes were chosen for an animal model due to
their average intravaginal surface area being very similar to
the average value measured in women (23,38,39). The human
validity of this particular model is subject to the caveat that
(what were judged to be) excessive amount of viscous mucus
were encountered during the cylindrical matrix sublimation
rate determinations described below.
For NOR and HMCS matrices, intravaginal sublimation
occurred (similar to in vitro measurements) at zero-order
(constant) rates (Fig. 4a and b), with the 4.5 fold in vivo
difference in erosion rates between the two materials being
similar if not equivalent to the 6.3 fold difference in rates
measured using the “accelerated” in vitro model. The fact that
the thermodynamically expected differences in sublimation
rates between NOR and HMCS were measured both in vitro
and in vivo, suggests that even for the most volatile of the
evaluated matrices the thermodynamically controlled surface
sublimation step remains rate limiting.
A requirement for ultimate success of any new drug deliv-
ery system is the ability to predictably function in vivo, and for
clinically successful HIV microbicides, the ability to provide
site specific delivery of adequate duration. We therefore
showed that in the case of the above formulations/devices
designed for intravaginal delivery of antiviral agents, differ-
ences in matrix-specific sublimation rates within ewes were
very similar to the differences measured using the controlled
convection “accelerated” in vitro method.
Demonstration of prolonged in vivo release achieving con-
tinuously virucidal concentrations of microbicides intravagi-
nally, is planned as the primary follow-up activity to sheep and
ex vivo experiments described in this study. Further studies will
determine the locally-achieved concentration-based pharma-
codynamics of leadingHIVmicrobicides at the administration
Fig. 4 Comparison of intravaginal sublimation rates in ewes for (a) NOR
and (b) HMCS matrices relative to “accelerated” rates obtained in vitro
under controlled convection conditions. Each plotted point represents a
mean ± SEM (N04).
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Fig. 5 (a) Viability of human
PBMC cells during 10 days
exposure to HMCS, PF-12, ADM
and CDD matrices. (b) Viability of
cultured T-lymphocytes and (c)
macrophages during 12 and
20 days exposures to HMCS,
PF-11, PF-12, and CDD matrices.
Data presented in (a), (b) and (c)
are expressed in percentage of
viable cells. The error bars in (a),
(b) and (c) represent standard
errors of duplicates. Data shown in
panels (a), (b) and (c) are each
representative of two independent
experiments. (d) Ex vivo viability of
human ectocervical tissue during
5 days exposure to CDD, PF-11,
and HMCS matrices. The data
represent the mean ± SD of three
independent tissues performed in
duplicate. The viability of the
N9-treated tissues were signifi-
cantly reduced from control
(untreated) tissues (P<0.05)
(Wilcoxon T-test).
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site, in macaques. More specifically, the agents will be intra-
vaginally delivered at a series of constant rates, using subliming
matrices incorporated into elastomeric vaginal rings (employed
to help assure long term dose retention), with extent and
duration of efficacy being determined through multiple viral
challenges.
Subliming Solid Matrices Were Nontoxic
During Prolonged Contact with Human Peripheral
Blood Monocytic Cells (PBMC cells), T-Lymphocytes,
Macrophages and Ectocervical Explants
Subliming solid matrix materials under investigation appear
to have low toxicity and acceptable biocompatibility. Hu-
man PBMC cell culture remained 100% viable after 10 days
exposure to partially immersed HMCS, PF-12, ADM, and
CDD matrix discs (Fig. 5a). Other intravaginal HIV-1 target
cells such as human T-lymphocytes (Fig. 5b) and macro-
phages (Fig. 5c) exhibited full viabilities over 12 and 20 day
periods of continuous exposure to HMCS, PF-11, PF-12,
and CDD pellets. A saponin control demonstrated intrinsic
sensitivity of each cell type to toxic substances. Viability of
ectocervical tissue after 5 days continuous exposure to the
different subliming matrix discs did not differ from control
tissue cultured in parallel (Fig. 5d). Nonoxonyl-9 (N9) served
as a toxic substance control. In summary, no evidence of
sub-acute toxicity was observed with any of the matrix
materials, whether evaluated in ectocervical tissue, macro-
phages, T-lymphocytes, or PBMC. This very preliminary
indication of low toxicity for our delivery system provides the
basis for more extensive future studies evaluating local irritation
potential, and chronic toxicology assessment intravaginally and
systemically. The ultimate clinical viability of sustained intra-
vaginal microbicide release in general, and the potentially long-
term intravaginal exposure to vaporized subliming solids, will
require demonstration of acceptable drug product toxicology
on a case by case basis for each particular microbicide plus
subliming matrix combination.
Release of Drugs from Subliming Matrix Prolonged
Antiviral Activity Measured in Human Ectocervical
Explants
To be a therapeutically relevant drug delivery system, espe-
cially in the context of extended duration microbicide de-
livery, drug loaded subliming matrices should provide
prolonged and continuous antiviral activities. A clinically
relevant ex vivo model for sexual infection examining residual
infectivity subsequent to multiple HIV challenge of human
extocervical explants, was used to demonstrate this capabil-
ity. A result typical of multiple challenge is for HIV-1 p24
concentrations to initially rise, then decrease upon challenge
cessation, and then continue to drop to a steady value
indicating the extent of residual infection (Fig. 6). The anti-
viral activity of microbicide candidates is determined by
whether the tissues are protected against infection, relative
to untreated controls. An advantage to using ectocervical
explants for product testing is that appropriate HIV-1 target
cells are present in the appropriate ratio. Using this model
(23,24), we determined whether a given subliming solid is
capable of delivering sufficient amounts of TDF or FTC to
the tissue and prevent HIV-1 residual infection after multi-
ple viral challenge. Over the course of the 21 day culture
period, viral challenge occurred every 3 to 4 days over the first
10 days of culture (4 independent exposures to HIV-1) with
treatment entailing either a single bolus administration of
TDF or FTC in solution prior to the first challenge, or
continuous release of TDF or FTC from PF-11 matrix discs
during and subsequent to challenges. After virus challenges
ceased, HIV-1 p24 levels decreased in the control explants, in
those treated with either TDF or FTC in solution, and those
treated with placebo matrices, to a constant level of 3.8 log10
pg/mL by day 17 of culture (Fig. 6).
The TDF/PF-11 and FTC/PF-11 treated explants con-
tinued to show further reduction in HIV-1 p24 concentra-
tions out to 21 days, indicating termination of infection.
Fig. 6 Effect of emtricitabine (FTC) and tenofovir disoproxil fumarate
(TDF) incorporated into PF-11 matrix pellets on HIV infection in ectocer-
vical explants. HIV-1 infection is monitored over 21 days by HIV-1 p24gag
protein detected in the basolateral culture supernatant. Endpoint immuno-
histochemistry was performed to confirm infection. The presence of infected
cells (red deposits) is indicative of p24-positive cells. The data presented are
the median ±95% confidence interval of three independent tissues and
representative immunohistochemistry figures.
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Fig. 7 Anti-HIV-1 activity prolongation of (a) tenofovir, (b) emtricitabine, and (c) bC5A in human macrophage cell culture during delivery from HMCS, PF-11,
PF-12, and CDDmatrices. Antiviral activity prolongation in TZM reporter cells due to release of (d) tenofovir, (e) emtricitabine, and (f) bC5A fromHMCS, PF-11,
PF-12, and CDD matrices. The error bars represent standard errors of triplicates.
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This was confirmed by immunohistochemistry which
showed absence of HIV-1 infected cells only in explants
which continuously received TDF or FTC. This is in con-
trast to explants treated with an unformulated TFV or FTC
single dose, or those serving as controls, all of which showed
no protection against residual infection (Fig. 6) as confirmed
by high levels of p24 (3.6 log10) still being measured at day
21, and presence of p24-positive cells (pink) visualized by
immunohistochemistry.
Release of the Three Dissimilar Drugs from Several
Subliming Matrices Prolongs Antiviral Activities
Measured in Human Macrophages and TZM Reporter
Cells
To further demonstrate the ability of subliming solid based
delivery to enhance and prolong antiviral activity of TDF,
bC5A, and FTC, durations of protection against HIV-1 chal-
lenge were determined using human macrophages and TZM
reporter cell cultures (40), maintained in a low convection
environment to provide an alternate approximation of the
vaginal interior. The panels in Fig. 7a-c show that for macro-
phages infected with HIV-1 (GFP), complete protection by all
three microbicides was maintained for at least 3 weeks, re-
gardless of whether the drug incorporating matrix material
was HMCS, PF-11, PF-12, or CDD. However, by the fourth
week only the microbicides incorporated into slowest sublim-
ing matrix (CDD) were still providing complete protection,
with durations of residual protection provided by the other
matrices being inversely proportional to their intrinsic rates of
sublimation (Fig. 2a and b). In comparison, unformulated
microbicides (aqueous solutions in culture medium) in all cases
provided fewer than 2 weeks of complete protection. Anti-
HIV-1 activity prolongation experiments employing TZM
reporter cells (Fig. 7d-f), cultured under the same low convec-
tion conditions, appeared to show complete elimination of
viral infection (at least out to 30 days) regardless of whether
the microbicide was TDF, FTC or bC5A, when released from
any of the four matrix materials. Aqueous solutions of the
microbicides on the other hand could not prevent re-
establishment of infections, which in all cases occurred after
only 7–12 days of continuous incubation.
To summarize, physicochemical and preliminary safety
evaluations of this delivery system correctly predicted the
benefits of subliming solids for prolongation of anti-HIV effect
during multiple viral challenge, as demonstrated ex vivo for
TDF and FTC released from PF-11 pellets onto ectocervical
explants. The ability of all three matrix incorporated micro-
bicides to protect both macrophages and TZM reporter cells
from a high dose viral challenge, even subsequent to their
continuous sublimation and release for several weeks, con-
firms the therapeutic potential of sublimation based drug
delivery for HIV prophylaxis prolongation. Sustained and
controlled delivery of a potentially large variety of active
agents through the sublimation of surrounding matrix may
shift the microbicide-based prevention of sexual HIV trans-
mission paradigm from one where mode and mechanism of
delivery (the formulation) is secondary to the biological prop-
erties of the specific microbicide drug substance, to one where
sustained unobtrusive intravaginal delivery will be essential for,
and successfully employed in, a majority of future prophylactic
vaginal microbicide products.
CONCLUSION
Providing a predetermined and broad range of release rates
and durations for a variety of structurally dissimilar HIV-1
drugs in a matrix enthalpy dependent manner is the first step
towards demonstration and development of an unprecedented
delivery system. Subliming solid based matrices appear to be
readily applicable to controlled release of many current and
future microbicide candidates where continuous and extended
duration administration would be therapeutically beneficial,
regardless of their molecular size, structure, or physiochemical
properties. A perhaps universal drug delivery capability for
implantable systems including intravaginal rings has therefore
been identified and is being actively investigated.
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